Medical Xpress June 28, 2022
Gunnar Bartsch, Julius-Maximilians-Universität Würzburg

In the fight against the COVID-19 pandemic, mRNA-based vaccines have impressively demonstrated their potential. Using this technology, scientists were able to rapidly develop and bring to market vaccines against SARS-CoV-2 that have been extremely effective at protecting millions of people against severe disease progression of COVID-19 or even death.

However, RNA-based medicine can be used to combat more than just viruses. Among others, it can also be considered as a candidate for a new type of antibiotics that can be used to treat bacterial infections in a tailored manner.

Which prerequisites these active agents need to fulfill and how they work in the bacterium—this has been investigated by researchers from the University of Würzburg (JMU). Teams from the Institute of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
GLP1 Drugs Not Tied to Pregnancy Loss, Birth Defects
FDA advisers to weigh first psychedelic therapy in early June
Verve moves forward with backup base editing therapy
STAT+: Young boy dies in trial for Pfizer Duchenne gene therapy
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply

Share This Article